Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2

Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2

Abstract Among the therapies against the pandemic SARS-CoV-2 virus, monoclonal Antibodies (mAbs) targeting the Spike glycoprotein represent good candidates to interfere in the Spike/ACE2 interaction, preventing virus cell entry. Since anti-spike mAbs, used individually, might be unable to block the...

Full description

Bibliographic Details
Main Authors: Margherita Passariello, Chiara Gentile, Veronica Ferrucci, Emanuele Sasso, Cinzia Vetrei, Giovanna Fusco, Maurizio Viscardi, Sergio Brandi, Pellegrino Cerino, Nicola Zambrano, Massimo Zollo, Claudia De Lorenzo
Format: Article
Language:English
Published: Nature Publishing Group 2021-05-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-90348-7

Internet

https://doi.org/10.1038/s41598-021-90348-7

Similar Items